Use of gastrointestinal prophylaxis in NSAID patients: a cross sectional study in community pharmacies
- 184 Downloads
Objective To assess the appropriateness of gastroprotective agents (GPA)\ NSAID use in patients’ access medication through community pharmacy and the factors associated with any inappropriateness found. Methods A cross-sectional study in which patients requesting NSAIDs through community pharmacy was undertaken. Information was collected through a structured questionnaire included data of patients’ pharmacotherapy and gastropathy risk factors. Patients were classified as “overprotected” or “underprotected” according to the use of gastroprotective-drugs and presence/absence of gastropathy risk factors. We calculated the risk for under-or over-protection using logistic regression controlling for potential confounders. Results Twenty-seven community pharmacies of Southeast of Spain participated in the study. Out of 670 NSAID users recruited in the study, 243 (36.3%) were not appropriately protected: 197(81.1%) patients were underprotected, and 46 (18.9%) patients were overprotected. Compared to patients with ulcer history, patients with cardiovascular disease or chronic morbidity (aOR 18.55; 95% CI l 3.68–93.52, P < 0.001) and aged over 60 years (aOR 23.97; 95% CI 3.93–145.9) were associated with underuse of gastroprotective-drugs. OTC-NSAID-users were more likely to be underprotected than those with medical prescription (aOR 3.47; 95% CI l 1.84–6.55). Conclusions Inappropriate GPA use is relatively frequent among NSAD users, especially in those using OTC-NSAIDs. Community pharmacists should be aware of factors contributing to NSAID-induced GI complications and assess its presence in the consumer when dispensing an OTC-NSAID.
KeywordsCommunity pharmacy Gastroprotective drugs Non Steroidal Antiinflammatory Drugs OTC-drugs Risk factors Spain
The authors would like to acknowledge the pharmacy students and the 27 participating community pharmacies for their support to the project.
We have not received any external financing for this project.
Conflicts of interest
- 5.Dirección General de Farmacia y Productos Sanitarios. Prestación Farmacéutica y Ortoprotésica de la Comunitat Valenciana, 2009;3.Google Scholar
- 6.Lanas A, Perez-Aisa MA, Feu F, Ponce J, Saperas E, Santolaria S, et al. Investigators of the Asociación Española de Gastroenterología (AEG). A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol. 2005;100:1685–93.PubMedCrossRefGoogle Scholar
- 11.Lanas A. Cost stratification of nonsteroidal anti-inflammatory drug-associated gastrointestinal side effects. Med Clin (Barc) 2000;114(3):46–53.Google Scholar
- 13.Association of the European Self-Medication Industry. The economic and public health value of self medication 2004: http://www.aesgp.be/ephv/2004study.pdf. Accessed 7 Feb 2011.
- 16.Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;4:CD002296.Google Scholar
- 17.Arboleya LR, De la Figuera E, García M, Aragón B, VICOXX Study Group. Management pattern for patients with osteoarthritis treated with traditional non-steroidal anti-inflammatory drugs in Spain prior to introduction of Coxibs. Curr Med Res Opin 2003;19:278–287.Google Scholar
- 24.Van Dijk KN, Ter Huurne K, De Vries CS, Van den Berg PB, Brouwers JR, De Jong-van den Berg LT. Prescribing of gastroprotective drugs among elderly NSAID users in The Netherlands. Pharm World Sci. 2002;24:100–3.Google Scholar